We have designed several prototype vaccines, a series of modality and antigen combinations that are expected to induce immunity.Among these multiple prototypes, we demonstrate that the SARS-CoV-2 express protein antigen fixed on the surface of its membranes binds to ACE2, which is a known SARS-CoV-2 receiver.
We also tested the induction of express antibodies opposed to the SARS-CoV-2 Spike protein through inoculating mice with those vaccine prototypes a unmarried intranasal dose.The induction of express antibodies opposed to this SARS-CoV-2 antigen was measured ELISA and in comparison tests.We have reduced vaccine prototypes to several applicants who have induced a more potent express antibody reaction for long run development.
Lately we are in the process of testing in vivo neutralizing antibody titers, in addition to this, we plan to perform the following tests.
Yuichi Iwaki, MD, Ph.D., president and ceo of MediciNova, Inc., said: “We are very pleased to verify that we now have several prototype cOVAD-19 vaccines that have induced a strong antibody reaction opposite the SARS protein.CoV-2 Spike after a single intranasal dose is given.This is a step in our progression to an effective vaccine.We look forward to posting more effects as soon as possible.»
About ACE2
ACE2 is an enzyme attached to the membranes of cells in the lungs, arteries, heart, kidneys and intestines.As a transmembranary protein, ACE2 serves as the number one access point to the cells of certain coronaviruses, adding HCoV-NL63, SARS-CoV (the virus that causes SARS) and SARS-CoV-2 (the virus that causes COVID-19).
About packing cells
About Master Cell Bank
From the mobile line of productive origin is produced a master mobile bank (MCB), which is periodically cryopreservate in several vials to avoid genetic variation and possible contamination by eliminating the total number of passes or manipulations of a mobile line the production process.
About the BC-PIV SARS-CoV-2 vaccine
BC-PIV, a state-of-the-art non-transmissible viral vector jointly developed through BioComo and Mie University, is derived from recombinant human parainfluenza virus type 2 (hPIV2). It is very effective in its ability to move multiple foreign proteins to the receptors and has a superior protection profile because no secondary infectious virus is produced. BC-PIV is designed to demonstrate not only the gene, but also the foreign protein on the surface and inside of the viral membrane. Thus, it can send out giant virus membrane proteins and sign receptor transducers / ligand proteins on the viral surface. BC-PIV is capable of delivering proteins that require a suitable three-dimensional or multimeric design while maintaining the design. BC-PIV reasons intelligent immunogenicity as opposed to antigenic proteins without adjuvants. The BC-PIV SARS-CoV-2 vaccine prototype was developed to come with the SARS-CoV-2 explicit antigenic protein in order to obtain explicit maximum antigenicity. The BC-PIV SARS-COV-2 vaccine may evolve as an intranasal vaccine in addition to intramuscular injection due to its strong affinity for the nasal mucosa and upper respiratory tract, which is the same direction of infection. SARS-CoV- 2. An intranasal vaccine deserves to induce local mucosal immunity. To date, BioComo has effectively produced a recombinant Ebola virus vaccine (https://www.nature.com/articles/s41598-019-49579-y) and a respiratory prefusion F syncytial virus vaccine (data not published) this BC-PIV technology platform.
BioComo, a biogeneration company founded in Mie Prefecture, Japan in May 2008, is building generation platforms to create new and leading vaccine-carrying leaders to improve immunity in collaboration with the Department of Microbiology and Molecular Genetics at mie University.they have already managed to reach a highly effective vaccine carrier and new adjuvants candidates. Its generation will be implemented for the production of next-generation vaccines to prevent infections such as RS, Ebola, influenza viruses and SARS-CoV-2.they also enable faster and more cost-effective production of these vaccines.BC-PIV is the generation of fundamental platform named after the company, BioComo, and the main carrier of vaccines derived from vectors of the recombinant human parainfluenza virus 2 (hPIV2).is committed to the invention of new vaccines for global infection threats as well as malignant tumors.
About MediciNova
MediciNova, Inc.es a publicly traded biopharmaceutical company founded on the acquisition and progression of new small molecule curative products for the remedy of medically ill-wishing diseases not satisfied with a number one advertising target in the US market.But it’s not the first time MediciNova’s existing strategy is to focus on the BC-PIV SARS-COV-2 Vaccine for COVID-19, MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and substance dependence (p., Alcohol-related disorder, methamphetamine dependence, opioid dependence), as well as the prevention of acute respiratory misery syndrome (ARSD) caused through COVID-19 and MN-001 (tipelukast) for fibriotic diseases such as nopitive steatohepatitis (NASH) and idiopathic pulmonary fibrosis (FPI) The pipeline MediciNova also includes MN-221 (bedoradrine) for the remedy of acute asthma exacerbations and MN-029 (denibuline) for counterfeit tumor cancers.(c) partnerships and other possible investment discussions to help further progress their programs.For more information about MediciNova, Inc., visit www.medicinova.com.
Statements in this press release that are not old-fashioned in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements come with, without limitation, statements regarding to run the progression and efficacy of the BC-PIV SARS-COV-2, MN-166, MN-001, MN-221 and MN-029 vaccines. These forward-looking statements would possibly be preceded, followed or in a different way would come with the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “possibly”, “could”, possibly “,” will “,” would “,” “,” plan “or similar expressions. These forward-looking statements involve a number of threats and uncertainties that could possibly cause actual effects or occasions that differ materially from those expressed or implied to through such forward-looking statements. Factors that would possibly cause actual effects or occasions to differ materially from those expressed or implied through such forward-looking statements come with, but are not limited to, threats to secure a long-term spouse or grant from investment for the progression of BC-PIV SARS-COV-2, MN-166, MN-001, MN-221 and MN-029 and threats to raise sufficient capital if necessary to finance MediciNova operations and their control . to the clinical progression, threats, and uncertainties inherent in clinical trials, adding the prospective cost, expected time, and threats related to clinical trials designed to meet FDA rules and the ability for further progression given those factors, product progression and marketing threats, uncertainty about whether clinical trial effects await results in later stages of product progression, threat of delays or inability to download or maintain regulatory approval Organize threats related to the use of third parties to sponsor and fund trials, threats related to high-level asset rights of product applicants and the ability to protect and enforce those intellectual asset rights, the threat of breach by third parties in which they are MediciNova bases it to conduct its clinical trials and manufacture its p candidate products to perform as intended, the threat of higher prices and delays due to delays in initiating, recruiting, completing or reviewing clinical trials or significant issues related to the fairness announcement of clinical trials. clinical trial designs or the execution of clinical trials, and the expected timing of submission to regulatory authorities, MediciNova collaborations with third parties, budget availability to carry out product progression plans, and MediciNova’s ability to secure investment of third parties for systems and to raise sufficient capital when necessary, and other threats and uncertainties described in the documents filed through MediciNova with the Securities and Exchange Commission, adding their annual report on Form 10-K for the year ended 31 December 2019 and your next periodic reports on Form 10-Q and reports on Form 8-K. We deserve not to place undue reliance on these forward-looking statements, which refer only to the date hereof. MediciNova denies any legal purpose or responsibility to review or update such forward-looking statements.